This has been another exciting year in outsourcing, as mergers, acquisitions, and other collaborations continued with CROs and CMOs moving toward functioning as strategic partners.
2014 was an exciting year in outsourcing. Several high profile mergers and acquisitions in both the CRO and CMO world will mean some familiar names will go through big changes — Huntingdon acquired Harlan, and PRA acquired RPS in the CRO world; Patheon acquired both DSM and Gallus Biopharma, and AMRI acquired Cedarburg and OsoBio in the CMO world.
The jury is still out on the ultimate impact of healthcare reform in general, and perhaps this impact is even murkier in the life sciences space. Certainly there will be very dramatic changes to the providers (hospitals, primary care, etc.) and payers (insurance companies, health plans, etc.), but it is more difficult to see exactly how the changes will manifest themselves for the remaining entities in the health sciences arena.
At the core of every drug development program is the challenge to successfully express active, high quality product, and this is especially true of biologics. Indeed, very frequently drug developers are faced with protein expression issues, struggling to express a specific protein for months (and sometimes years) with varying degrees of success; low or no expression, insoluble expression, proteolytic clipping of the expressed protein or a combination thereof are examples of the hurdles encountered in product development efforts. Such challenges in protein expression are a major source of biopharmaceutical development delays, particularly as production strain development is typically performed in a linear and iterative fashion.
Data compiled from a strategic partner survey for outsourcing commercial-scale drug substance projects in API manufacturing revealed the differences in how buyers think about strategic partnerships with contract manufacturers.
Suppliers qualify for partner status when they share risk and responsibility, more than size and capabilities.
Outsourcing can enable cost cutting and taking advantage of specialized expertise. But the complexity can also open the door to errors, rework, product delays, and compliance issues. Here are three items that should be on your data management short list when outsourcing.
The healthcare contract research outsourcing market is expected to grow from $25.1 billion in 2011 to $65 billion by 2018. Eight industry experts discuss how to turn your CRO into a strategic partner.
In 2013 we can anticipate a new type of relationship emerging due to the steady demand among buyers of outsourced services for drug delivery support.
Nice Insight’s survey asked outsourcing buyers to separate the essential qualities of an outsourcing relationship from the nonessential, and the essential qualities varied by the buyer category and business size.
In Life Sciences business relationships, quality, reliability, and communication have to occur for both the client and the CMO to achieve their common goal.
Life Science Leader magazine posed a series of questions to industry experts to gain insights on how they assess CMO attributes.
Nice Insight’s pharmaceutical and biotechnology outsourcing survey, 10% indicated that innovativeness was the most important attribute when selecting a CRO or CMO. By Eric Langer, president and managing partner, BioPlan Associates, Inc. By Eric Langer, president and managing partner, BioPlan Associates, Inc.
Nice Insight’s pharmaceutical and biotechnology outsourcing survey, 10% indicated that innovativeness was the most important attribute when selecting a CRO or CMO. By Kate Hammeke, research manager, Nice Insight
Life Science Leader’s roundtable with seven experts provides insight to help gain greater understanding of the CRO selection process. By Rob Wright, Chief Editor, Life Science Leader magazine
Each business has its own approach to outsourcing, from functional to full service, and often that approach is dependent on the requirements of a specific project. By Kate Hammeke, research manager, Nice Insight